Cover of MAP - Market Access Podcast

MAP - Market Access Podcast

MAP - Market Access Podcast

By: Dr. Stefan Walzer
Listen for free

Season's Savings | 0.99 €/month for 3 months

5.99 €/month thereafter - terms apply. Cancel monthly.
Summary
 Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world. MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market access , reimbursement and pricing issues in the D-A-CH countries and around the world. With MAP you will get a summary of core market access systems and processes as well as latest changes in regulations including statements and opinions of core decision makers and stakeholders from various countries. The CEO and founder of MArS is also the driver behind MAP: Dr. Stefan Walzer works in the field of payer strategy, pricing, health economics and reimbursement since 2004 and is the founder and CEO of MArS Market Access & Pricing Strategy GmbH based in Germany. MArS makes it as easy as possible for you to get your Pharmaceutical, MedTech or digital health product to the market and of course get the price it deserves. Stefan previously worked as a payer consultant for various global pharmaceutical and medical device / diagnostic companies, successfully launching their products across the world. He was the Global Payer Strategy Leader for various products and compounds at F. Hoffmann – La Roche AG, where he successfully developed early payer strategies as well as launching and maintaining the reimbursement process for top brands and early compounds. Stefan is capable in translating the clinical and economic evidence into successful reimbursement submissions and pricing negotiations especially in Austria, Germany and Switzerland. Additionally he teaches market access, pricing and negotiations at the State University of Baden-Wuerttemberg and the University of Applied Sciences Weingarten-Ravensburg (both Germany). Besides other roles and responsibilities. Stefan was the head of the committee “Inpatient care” of the German Health Economic Association (DGGÖ). Furthermore he is also a member of the Austrian Health Economic Association (ATHEA) and the Swiss Health Economic Association (SGGÖ). Additionally, he is a member of the Access Advisory Committee of the Global Pneumonia Prevention Coalition. Stefan received a Master of Science in Economics from the University of Tuebingen (Germany), a PhD in Health Economics from the University of Zurich (Switzerland) and a post-graduate diploma in Clinical Trials from the London School of Hygiene and Tropical Medicine (UK). He is co-author of more than 40 peer-reviewed scientific articles and more than 300 scientific abstracts.Copyright 2026 Dr. Stefan Walzer Economics Hygiene & Healthy Living Physical Illness & Disease Science
Episodes
  • How Can HEOR Teams Build Trust in AI-Generated Models, Haidong Feng?

    How Can HEOR Teams Build Trust in AI-Generated Models, Haidong Feng?
    1 Nov 2026

    AI is reshaping health economics and outcomes research (HEOR) – but where does it truly belong? In this MAP episode, Dr. Stefan Walzer talks with Haidong Feng, Associate Principal Scientist at Merck, about “human in the loop” versus “AI in the loop” and why the two complement rather than contradict each other.

    Haidong explains why HEOR teams should reshape entire workflows – from evidence retrieval to modeling, validation and documentation – instead of replacing single tools like Excel or R, and why human experts remain essential in deciding where validation is needed. They also discuss how to earn the trust of HTA bodies in AI-supported models, which new skills modelers will need, how organizations can connect AI workflows across functions, and why the biggest barrier ahead is people, not technology.

    Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts — and if you enjoyed the episode, don't forget to rate it and the podcast!

    MAP is the first and only bi-weekly market access podcast provided by MArS — and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

    #MarketAccess #HEOR #HealthEconomics #AI #HumanInTheLoop #AIintheLoop #HTA #Pharma #PricingStrategy #MAPPodcast
    Show more Show less
    39 min
  • Can US GLOBE and GUARD Models Really Lower Drug Prices, Brittany La Couture?

    Can US GLOBE and GUARD Models Really Lower Drug Prices, Brittany La Couture?
    15 Oct 2026

    When the US benchmarks drug prices against other countries, the whole world feels it. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Brittany La Couture of Applied Policy, a health policy attorney with eight years at the Centers for Medicare & Medicaid Services, to unpack the US “most favored nation” approach to drug pricing and the three CMMI models behind it: GENEROUS, GLOBE and GUARD.

    They discuss why providers and patients may carry the cost, why Brittany sees the models as a tax on manufacturers rather than a price cut, and whether launch delays in Europe point to a more fragmented global market.

    Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts — and if you enjoyed the episode, don't forget to rate it and the podcast!

    MAP is the first and only bi-weekly market access podcast provided by MArS — and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

    #MarketAccess #DrugPricing #MostFavoredNation #MFN #GLOBEModel #GUARDModel #CMMI #HealthPolicy #HealthEconomics #Pharma #PricingStrategy #MAPPodcast
    Show more Show less
    45 min
  • What Will It Take to Keep Biotech Growing in Europe, Rainer Westermann?

    What Will It Take to Keep Biotech Growing in Europe, Rainer Westermann?
    1 Oct 2026

    In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Rainer Westermann, Chairman of the Life Sciences Acceleration Alliance (LSAA), to ask whether Europe can remain a globally competitive home for life sciences innovation — and what has to change for new therapies to reach patients.

    Bringing an investor's lens, Rainer explains why so many promising European companies scale in the US instead: the "valley of death" between great science and a viable business, the shortage of productive growth capital, the absence of a deep, liquid capital market, and the drag of long timelines, fragmented member-state systems, and cost-containment-first thinking. They also unpack the ripple effects of the US Most Favored Nation policy, the patent cliff, and why patients — who are also voters — belong at the center of the debate.

    Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts —and if you enjoyed the episode, don't forget to rate it and the podcast!

    MAP is the first and only bi-weekly market access podcast provided by MArS—and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/

    #MarketAccess #LifeSciences #Biotech #VentureCapital #PharmaInnovation #HealthcareInvestment #EuropeanUnion #MFN #MarketAccessStrategy #marketaccesspodcast
    Show more Show less
    42 min
adbl_web_anon_alc_button_suppression_t1
No reviews yet